TP53 and medulloblastoma: In SHH-activated tumors, TP53 should be sequenced with validated methods in certified laboratories to clearly differentiate between the SHH-activated medulloblastoma entities with and without TP53 alteration because of important consequences for treatment decisions and possible germ line alterations.